Dr. Diller highlighted in Front Page New York Times Article

I had the recent opportunity to work closely with Alan Schwarz of the New York Times on an article he was writing to highlight the lack of reliable information for patients and doctors on the use of multiple psychiatric drugs for children.  Alan approached me and asked if he could use one of my families to highlight the dilemmas facing parents.  Matthias's mother, Joelle, kindly consented, and their story is told in the article which ran on the front page on November 15th, and can be accessed by clicking: http://www.nytimes.com/2014/11/15/us/one-drug-or-2-parents-see-risk-but-also-hope.html?module=Search&mabReward=relbias%3Ar%2C{%221%22%3A%22RI%3A7%22}&_r=0. There are some nice photos of the family and even one of me in the article.


Lawrence Diller, M.D. will be speaking for the Modesto Area Partners in Science (MAPS) at the Modesto Junior College (MJC), West Campus Sierra Hall 132, on Friday, October 17th at 7:30 PM.  The title of his talk is "ADHD: Models, Myths and Medication."  Admission and parking are free. 

Coming Soon to a Neighborhood Near You: Adderall Abuse

First Appeared in the Huffington Post

April 8th, 2014


The rise of both the ADHD/ADD diagnosis and the use of stimulant drugs like Adderall, Concerta and Ritalin is once again front page news. A Centers for Disease Control (CDC) telephone survey found that nearly one in five high school boys' parents have been told their child has ADHD/ADD. Express-Scripts, the largest prescription insurance processor, in a recent report confirmed the highest prescription rates in boys but also documented explosive growth in prescriptions for adults with ADHD/ADD.

Telephone surveys and prescription rates are interesting but indirect measures of the use of stimulant drugs in the United States. However, the Drug Enforcement Administration (DEA) maintains records of the annual quotas approved for production by drug companies in the United States for controlled substances like the stimulants. While the manufacturing quotas do not specifically indicate how much drug is actually taken by Americans, it is unlikely that drug companies would request a higher quota than they believed they could sell -- and if someone buys the drug, they are likely to take it.

Read more ...